SCHEMBL7227264

SCHEMBL7227264

Nc1cc(Cl)cc2c1-c1c(Cl)cc(Cl)cc1C2=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 2/20 0.42
DNMT1 P26358 1/20 0.42
HSP90AA1 P07900 1/20 0.40
CYP3A4 P08684 4/20 0.39
TSHR P16473 3/20 0.38
TP53 P04637 2/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
TDP1 Q9NUW8 3/20 0.38
ALDH1A1 P00352 3/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
POLB P06746 2/20 0.38
MAPT P10636 2/20 0.38
NPC1 O15118 1/20 0.38
THRB P10828 1/20 0.38
APEX1 P27695 1/20 0.38
RECQL P46063 1/20 0.38
RAB9A P51151 1/20 0.38
BLM P54132 1/20 0.38
MCL1 Q07820 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10702044 0.86 HSP90AA1 (0.42) CES1DNMT1HSP90AA1CYP3A4TSHR
SCHEMBL5681748 0.86 CES1 (0.52) CES1DNMT1HSP90AA1CYP3A4TSHR
SCHEMBL11601993 0.79 CES1 (0.50) CES1DNMT1HSP90AA1CYP3A4TSHR
SCHEMBL8745733 0.78 ADORA2A (0.60) DNMT1CYP3A4TSHRTP53MEN1
SCHEMBL6905214 0.72 TTR (0.64) DNMT1MEN1KMT2ATDP1POLB
SCHEMBL16870940 0.72 TTR (0.54) CES1DNMT1HSP90AA1MEN1KMT2A
SCHEMBL31154504 0.72 TTR (0.54) CES1DNMT1HSP90AA1MEN1KMT2A
SCHEMBL8987675 0.72 HSP90AA1 (0.67) CES1DNMT1HSP90AA1TP53TDP1
SCHEMBL8663125 0.72 ALDH1A1 (0.43) CYP3A4TSHRTP53MEN1KMT2A
SCHEMBL9846520 0.71 ELANE (0.53) HSP90AA1CYP3A4TSHRTP53MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6545011-B2 PARP (poly(adenosine 5'-diphospho-ribose) polymerase) inhibitors GUILFORD PHARMACEUTICALS INC. 2003-04-08 US disclosed
US-20020037904-A1 Substituted 4,9-dihydrocyclopent a [imn] phenanthridine-5-ones, derivatives thereof and their uses EISAI INC. 2002-03-28 US disclosed
WO-2002006240-A1 SUBSTITUTED 4,9-DIHYDROCYCLOPENTA[IMN] PHENANTHRIDINE-5-ONES, DERIVATIVES THEREOF AND THEIR USES GUILFORD PHARMACEUTICALS INC. (US) 2002-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037904-A1 Substituted 4,9-dihydrocyclopent a [imn] phenanthridine-5-ones, derivatives thereof and their uses PARP1, PARP2, PARP4 CES1 4159/4885DNMT1 239/4885HSP90AA1 2984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.